AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02148575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Group
Study NCT02148575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Management Group
Study NCT00556478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PSD502, contains a mixture of lidocaine and prilocaine
Description: PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
Study NCT00556478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
Study NCT01974843 — intervention group
Intervention type: DRUG
Intervention: Levobupivacaine
Description: in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
Study NCT01974843 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Description: in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
Study NCT06796010 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
Study NCT06796010 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Untreated zone
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study NCT03657134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CoVa-2 Monitoring System
Description: Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
Study NCT02993822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant Maleate
Description: Tablet, once daily, oral
Study NCT02993822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily, oral
Study NCT02565264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma-derived exosomes
Description: Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
Study NCT00670618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC Tooth Mousse)
Description: Calcium and phosphate
Study NCT00670618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC MI Paste Plus)
Description: Calcium, phosphate and fluoride
Study NCT00670618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride (Elmex Medical Gel)
Description: Fluoride
Study NCT02700035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bii-Zin-Da-De-Dah (Listening to One Another)
Description: Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
Study NCT03122808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine Activity Analysis
Description: Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
Study NCT03122808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Partogram Analysis
Description: Analysis of slope of partogram
Study NCT02337998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: load carriage
Study NCT04223765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.k.28
Description: Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).
Study NCT04223765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day IV for 3 consecutive days
Study NCT04223765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day IV for 3 consecutive days
Study NCT04223765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 70 mg/m\^2/day administered over 3 consecutive days.
Study NCT02047773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration
Description: If bacterial load checked on day 7 is less than 10\^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10\^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
Study NCT02047773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colomycin
Description: If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
Study NCT02047773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colomycin
Description: If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
Study NCT02047773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Study NCT01369472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule
Description: single oral administration in period 1 or 2, 3 for each sequential group.
Study NCT03874741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200
Study NCT02105558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: ￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
Study NCT02105558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined spinal and epidural anesthesia
Description: A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
Study NCT02594670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DU20 and HT7 combination
Description: acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
Study NCT02594670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DU20 and SP6 combination
Description: acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
Study NCT02594670 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DU20 and SA combination
Description: Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
Study NCT02677207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Study NCT02677207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Study NCT02643563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
Study NCT02643563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 1%
Description: Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
Study NCT04381598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo without the active drug will be placed in the control sites.
Study NCT05367648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elio
Description: Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
Study NCT02643563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% + epinephrine 1:200,000
Description: Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
Study NCT04463186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Static Stretching
Description: Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
Study NCT00516373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral
Study NCT01917981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal Heart Rhythm Monitor
Study NCT00384930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
Study NCT00384930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet by mouth once a day for twelve weeks.
Study NCT00384930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tadalafil tablet by mouth once a day for twelve weeks.
Study NCT00384930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet by mouth once a day for twelve weeks.
Study NCT00384930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth one a day for twelve weeks
Study NCT02655783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
Study NCT02655783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
Study NCT02655783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
Study NCT01302600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olesoxime
Description: Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
Study NCT04129268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometry exercise at 60% VO2max
Description: Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
Study NCT04129268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cycle ergometry exercise at 60% VO2max
Description: Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
Study NCT05367648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT01595971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing education
Description: Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
Study NCT01595971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Received the usual care provided
Study NCT04610268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
Study NCT01874132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
Study NCT00712127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: The participants in this intervention will receive 12 months of weight loss through diet and exercise
Study NCT00712127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise-Delayed
Description: Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
Study NCT03021122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PedAMINES™ / Conventional Method
Description: Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)
Study NCT03021122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Method / PedAMINES™
Description: Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)
Study NCT02897037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
Study NCT02897037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: heparin monotherapy
Study NCT01519544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temazepam
Description: Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
Study NCT01519544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
Study NCT03973554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pearl powder
Description: natural product, support bone and joint health
Study NCT03973554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP
Description: Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
Study NCT01253148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere® Yttrium-90 (Y-90) Microspheres
Description: Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
Study NCT02696057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual technics
Description: soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
Study NCT02696057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: spinal stabilization exercise applied three sessions per week, totally six week.
Study NCT03136497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg ABT-199
Description: Oral dose daily until disease progression
Study NCT03136497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral dose daily until disease progression
Study NCT03136497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
Study NCT03136497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg ABT-199
Description: Oral dose daily until disease progression
Study NCT00735826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
Study NCT04597216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sample of blood and saliva
Description: sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
Study NCT02970630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: once a day
Study NCT02970630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: twice daily
Study NCT03069248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT03069248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Interferon
Study NCT03273647 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes.
Study NCT04246775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Peristeen
Description: rectal irrigation
Study NCT03951831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
Study NCT03951831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
Study NCT03951831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.